Document is current
Any future updates will be listed below
-
Authors
Almekinders, Cornelia A. M.
Lin, Lishi
Beijnen, Jos H.
Sonke, Gabe S.
Huitema, Alwin D. R.
Dezentjé, Vincent O.
- License Information
-
More Information
Article History
Received: 27 March 2024
Accepted: 28 October 2024
First Online: 7 November 2024
Declarations
:
: Authors C.A.M. Almekinders, L. Lin, A.D.R. Huitema declare that they have no relevant financial or non-financial interests to disclose. J.H. Beijnen is part-time employee and (indirect) shareholder of Modra Pharmaceuticals BV. He is (partly) patent holder of oral taxane formulations which are clinically developed by Modra Pharmaceuticals BV (a spin-off company of the Netherlands Cancer Institute), with no influence on this work. G.S. Sonke receives research grants from Agendia, AstraZeneca, Merck, Novartis, Roche and Seagen, with no influence on this work. V.O. Dezentjé receives consulting fees from AstraZeneca, Novartis and Daiichi Sankyo, with no influence on this work.
: The conduct of this retrospective observational study was approved by the Investigational Review Board of the NKI-AvL.
: The need for written informed consent was waived.
: Not applicable.
